ESTRO meets Asia 2024 - Abstract Book

S266

Interdisciplinary – SBRT

ESTRO meets Asia 2024

Our study suggests the potential utility of mean PTV doses to predict treatment outcomes and optimise treatment strategies 2 . This includes identifying patients who may benefit from alternative precision radiotherapy (RT) techniques, including proton beam therapy or real time adaptation, (e.g., MR-guided Adaptive RT) to maintain higher mean PTV-BED 10 doses. Prospective studies are warranted to validate our findings and refine treatment strategies in this patient population.

Keywords: SABR, liver, oligometastasis

References:

1. NHS England. (2020). Clinical Commissioning Policy: Stereotactic Ablative Body Radiotherapy (SABR) for Metachronous Extracranial Oligometastatic Cancer. Retrieved from: https://www.england.nhs.uk/wp content/uploads/2020/03/1908-cc-policy-sbar-for-metachronous-extracranial-oligometastatic-cancer.pdf

2. Sanford NN, Timmerman RD. Optimizing Risk Vs. Reward in the Era of Ablative Radiotherapy Through Calculated Useful Trauma (CUT). Int J Radiat Oncol Biol Phys. 2024 Feb 14:S0360-3016(23)08248-2.

243

Proffered Paper

Early complete tumor response as a survival predictor in HCC patients receiving SBRT

Qi-Qiao Wu 1 , Zhao-Chong Zeng 2

1 Radiation Oncology, Fudan University Zhongshan Hospital(Xiamen Branch), Xiamen, China. 2 Radiation Oncology, Fudan University Zhongshan Hospital, Shanghai, China

Purpose/Objective:

To evaluate the different response patterns after Stereotactic Body Radiation Therapy (SBRT) and their predictive value in local control and progression of hepatocellular carcinoma (HCC).

Material/Methods:

Seventy-two HCC patients who were treated with SBRT during 2015-2020 were included in this retrospective study. The assessment was made using MRI, CT, and PET-CT. Local and systemic responses were determined according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria during follow up. Patients were categorized as early responders (complete response during 6 months after radiotherapy) or non-early responders (the rest of the patients). Prognostic factors were determined using multivariate logistic models.